News stories about Lumenis (NASDAQ:LMNS) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lumenis earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 44.8955897798361 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Lumenis (LMNS) Stock Price” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3226434/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-lumenis-lmns-stock-price.html.
Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies.
Receive News & Ratings for Lumenis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumenis and related companies with MarketBeat.com's FREE daily email newsletter.